Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00086489
Other study ID # A3671002
Secondary ID
Status Completed
Phase Phase 2
First received July 1, 2004
Last updated June 5, 2012
Start date August 2003
Est. completion date May 2009

Study information

Verified date June 2012
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date May 2009
Est. primary completion date May 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed: Stage III (AJCC 6th edition)xxl unresectable melanoma, with measurable disease (either locally relapsed unresectable, in-transit lesions or unresectable draining nodes) or Stage IV melanoma, including:

- Metastasis to skin, subcutaneous tissues or distant lymph nodes, or

- Metastasis to lungs, or

- Metastasis to all other visceral sites with either LDH <= ULN (upper limit of normal) or a single site of metastasis

- Note: Patients with melanoma of ocular origin will be considered ineligible

- Documented progressive disease following adjuvant therapy, localized therapy or other therapy for metastatic disease

- Measurable disease defined by at least one target lesion that can be accurately measured and whose size is at least 1.0 cm (by spiral CT) or 2.0 cm (by conventional techniques) in its longest diameter

- ECOG performance status of 0 or 1 Life expectancy of > 3 months

- Either gender, aged 18 years and above

- Adequate bone marrow, hepatic, and renal functions determined within 2 weeks prior to starting therapy, defined as:

- Absolute neutrophil count >= 1.5 x 10(9)cells/L

- Platelets >= 100 x 10(9)/L

- Hemoglobin >= 10 g/dL

- Aspartate and alanine aminotransferases (AST, ALT) <= 2.5 x ULN (<= 5 x ULN, if documented liver metastases are present)

- Total bilirubin <= 1.5 x ULN

- Creatinine <= 1.5 x ULN

- Patients must have recovered from all prior treatment related toxicities, to baseline status, or a CTC grade of 0 or 1. Post-surgical pain shall not be considered a basis for exclusion.

- Females must either be not of childbearing potential [surgically sterilized, which includes tubal ligation, or at least 2 years postmenopausal; not breastfeeding], or practicing 1 form of approved contraception for at least three months prior to entry into the study with 1 of the following methods: (a) oral contraceptives, (b) intrauterine device, (c) implanted contraceptive (such as Norplant®), (d) injected contraceptives (such as Depo-Provera®), (e) diaphragm, (f) sexual partner must use condom or be surgically sterilized, or (g) sexually inactive. Females of childbearing potential must be instructed to avoid pregnancy during study participation. Negative serum or urine pregnancy test must be documented during screening evaluation.

- Must be willing and able to provide written informed consent.

Exclusion Criteria:

- Received immunotherapy for cancer within one month prior to the start of screening

- Patients previously treated on this protocol

- History of, or significant evidence of risk for, chronic inflammatory or autoimmune disease (e.g. Addison's disease, asthma, celiac disease, multiple sclerosis, Graves Disease, Hashimoto's thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, etc.)

- Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history.

- History of autoimmune colitis or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin.

- Pregnant or lactating women.

- Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.

- Diagnosed or suspected brain metastases. Patients with past history of brain metastases but with no radiologic evidence within 12 weeks prior to enter into the protocol will be eligible.

- Any serious uncontrolled medical disorder or active infection, which would impair their ability to receive study treatment.

- Coexisting malignancies except for basal or squamous cell carcinoma of the skin.

- Received any prior CTLA4 inhibiting agent

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
CP-675,206
pts treated at 10 mg/kg dose level on a monthly regimen
CP-675,206
pts treated at 15 mg/kg dose level on a quarterly regimen

Locations

Country Name City State
United States Research Site Ann Arbor Michigan
United States Research Site Ann Arbor Michigan
United States Research Site Chicago Illinois
United States Research Site Houston Texas
United States Research Site Los Angeles California
United States Research Site Nashville Tennessee
United States Research Site Pittsburgh Pennsylvania
United States Research Site Pittsburgh Pennsylvania
United States Research Site Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety At every scheduled visit for a maximum of 2 years from first dose of study drug No
Primary Tumor response Assessed every 2-3 months up to 2 years from first dose of study drug No
Secondary Monitor for human anti-human antibodies at the end of the study Pre-dose (Cycle 1 only) and end of study No
Secondary Explore genetic influences on safety and or immune response Pre-dose, Cycle 1 No
Secondary Assess PK during treatment All cycles as pre-specified in protocol No
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT04074096 - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Phase 2
Completed NCT02935790 - Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab Phase 1
Recruiting NCT05478876 - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract N/A
Completed NCT01211262 - Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Phase 1
Recruiting NCT03649529 - Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy Early Phase 1
Completed NCT03278665 - 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy Phase 1/Phase 2
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01455259 - Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors Phase 1/Phase 2
Completed NCT00978913 - Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00350597 - GM-CSF as Adjuvant Therapy of Melanoma Phase 2
Completed NCT00336986 - Efficacy Study of IL-21 to Treat Metastatic Melanoma Phase 2
Completed NCT02523313 - Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED Phase 2
Completed NCT03545334 - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study N/A
Completed NCT04253574 - Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
Completed NCT00179608 - Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy Phase 1
Terminated NCT00104884 - FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Phase 2